Back to List

Shionogi & Co., Ltd.

shionogi.co.jp

Shionogi & Co., Ltd. (Shionogi) represents drug discovery-based pharmaceutical company. We accordingly are focused squarely on in-house drug discovery.

Shionogi strives constantly to supply the best possible medicine to protect the health and wellbeing of the patients we serve. As a pharmaceutical company, we are focusing on SDGs (Sustainable Development Goals) Goal 3 : “Good health and well-being”. Formulation of “Shionogi global health access policy” is our determination to increase global health care access.

Shionogi as drug discovery-based pharmaceutical company, designed Medium-Term Business Plan “SGS2020”. We are focusing on infectious diseases and pain / CNS disorders as therapeutic areas where we can maximize our strengths in small-molecule drug discovery. Our strong position in infectious disease treatments is well-recognized, to the extent that the Shionogi name is synonymous with antibiotics in Japan.

COLLABORATIONS

SHOWING 5 of 6 COLLABORATIONS

See All

Access Accelerated Initiative

Tackling the growing burden of non-communicable diseases in low and middle-income countries and supporting...

Access Accelerated, Almirall, Astellas Pharma Inc, Bayer AG, Bristol-Myers Squibb, Celgene, Chiesi Farmaceutici, Chugai Pharmaceutical, Daiichi Sankyo, Eisai, Eli Lilly and Company, F. Hoffmann – La Roche Ltd., International Federation of Pharmaceutical Manufacturers & Associations, Johnson & Johnson, Menarini Group, Merck, MSD, Novartis, Pfizer Inc, Sanofi, Servier, Shionogi & Co., Ltd., Sumitomo Dainippon, Takeda Pharmaceutical Company Limited, UCB

SHOWING 5 of 6 COLLABORATIONS

See All